Matthew Okkerse Portfolio
Invests via Dauntless Investment Group LLC | Managed by Matthew Okkerse
Invests via Dauntless Investment Group LLC
Managed by Matthew Okkerse
Automatically Tracked
Private markets investor and operator focused on growth-stage technology and services businesses. Matthew Okkerse is known for leading deal sourcing, due diligence and portfolio value creation at mid-sized buyout and growth equity funds, and engages with LPs on strategy and reporting. Experienced in financial planning, operations and go-to-market scaling, he has overseen add-on acquisitions and exit readiness. Background includes roles in corporate finance and strategy and academic credentials in economics and finance. Market-facing strengths include cross-border sourcing, operational improvement and capital structuring.
Private markets investor and operator focused on growth-stage technology and services businesses. Matthew Okkerse is known for leading deal sourcing, due diligence and portfolio value creation at mid-sized buyout and growth equity funds, and engages with LPs on strategy and reporting. Experienced in financial planning, operations and go-to-market scaling, he has overseen add-on acquisitions and exit readiness. Background includes roles in corporate finance and strategy and academic credentials in economics and finance. Market-facing strengths include cross-border sourcing, operational improvement and capital structuring.
Investment Philosophy & Strategy
Focuses on growth-stage technology and services companies, blending buyout rigor with growth-equity agility. Emphasizes active, operationally-driven value creation: go-to-market scaling, FP&A-led performance improvement, and accretive add-on M&A. Underwrites opportunities with cross-border sourcing advantages and pragmatic capital-structure solutions to balance growth funding and downside protection. Prefers mid-market situations where hands-on governance, exit planning, and management alignment accelerate EBITDA conversion. Time horizon is multi-year with staged capital deployment and clear operational KPIs guiding follow-on investments and exit timing.
Focuses on growth-stage technology and services companies, blending buyout rigor with growth-equity agility. Emphasizes active, operationally-driven value creation: go-to-market scaling, FP&A-led performance improvement, and accretive add-on M&A. Underwrites opportunities with cross-border sourcing advantages and pragmatic capital-structure solutions to balance growth funding and downside protection. Prefers mid-market situations where hands-on governance, exit planning, and management alignment accelerate EBITDA conversion. Time horizon is multi-year with staged capital deployment and clear operational KPIs guiding follow-on investments and exit timing.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
-4.83%
Gain +1.84%
Monthly
-0.23%
Yearly
-2.73%
Drawdown
37.87%
$40.79M
Equity
Holdings
$40.79M
Investment
$56.33M
-$7.71M
Profit +$755,935.83
Realized
$7.83M
Unrealized
-$15.54M
Dividends
$341,458.82
Goals
Avg. 0% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
1.84%
Profit
$755,935.83
Win %
28%
This Week
Compared To Last Week
Gain
-6.97%
Profit
-$3.07M
Win %
28%
This Month
Compared to last month
Gain
-7.76%
Profit
-$3.45M
Win %
28%
This Year
Compared to last year
Gain
-28.88%
Profit
-$16.66M
Win %
36%
ARMP Armata Pharmaceuticals Inc.
+9.17%
+$51,992.21 
FEMY Femasys Inc.
+8.65%
+$252,178.24 
CAPR Capricor Therapeutics Inc.
+7.66%
+$0.51 
COUR Coursera Inc.
+6.09%
+$66,130.45 
ESTA Establishment Labs Holdings Inc.
+6.03%
+$89,790.72 
KZIA Kazia Therapeutics Ltd Sponsored ADR
+5.67%
+$136,370.08 
LCTX Lineage Cell Therapeutics Inc.
+5.59%
+$5.14 
NOW ServiceNow, Inc.
+5.54%
+$79,101 
AEON Aeon Biopharma Inc.
+5.37%
+$153,628.89 
INMB Inmune Bio Inc.
+4.69%
+$7.5 
AEM Agnico Eagle Mines Limited
+4.43%
+$1,293.6 
JOE The St. Joe Company
+3.87%
+$92,225.85 
STIM Neuronetics Inc.
+3.18%
+$22,151.22 
UPWK Upwork Inc.
+2.91%
+$16,581.6 
PTCT PTC Therapeutics, Inc.
+2.67%
+$16,206.87 
DC Dakota Gold Corp
+2.19%
+$66.81 
IRS IRSA Inversiones y Representaciones Sociedad Anónima
+1.88%
+$32,888.27 
UTI Universal Technical Institute Inc.
+1.87%
+$10,636.2 
PPC Pilgrim's Pride Corporation
+1.69%
+$6,723.29 
CIB Bancolombia S.A.
+1.49%
+$640.13 
ERNA Eterna Therapeutics Inc.
+1.42%
+$180 
TLPH Talphera Inc.
+1.42%
+$11,190.76 
CRESY Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria - American Depositary Receipt
+1.39%
+$12,428.83 
WELL Welltower Inc.
+1.33%
+$1,918.9 
LOMA Loma Negra C.I.A.S.A. Sponsored ADR
+1.31%
+$14,974.18 
SNDA Sonida Senior Living Inc.
+1.23%
+$1,549.24 
CALM Cal-Maine Foods Inc.
+1.22%
+$1,987.37 
DSL DoubleLine Income Solutions Fund
+1.09%
+$34.23 
MLP Maui Land & Pineapple Company, Inc.
+0.95%
+$2,710.68 
INVA Innoviva Inc.
+0.92%
+$312.82 
GGAL Grupo Financiero Galicia S.A. ADR
+0.91%
+$1,362.22 
ADAG Adagene Inc.
+0.87%
+$10,744.6 
LINC Lincoln Educational Services Corporation
+0.84%
+$5,898.74 
PPLT abrdn Physical Platinum Shares ETF
+0.79%
+$27.6 
TRAW Traws Pharma Inc.
+0.4%
+$128.92 
COLO Global X MSCI Colombia ETF
+0.35%
+$88.72 
BKD Brookdale Senior Living Inc.
+0.2%
+$91.42 
NWAX-UN New America Acquisition I Corp.
+0.2%
+$3.44 
CRIS Curis Inc.
+0.03%
+$0.1 
AZTR Azitra Inc.
0%
$0 
JAN JanOne Inc
0%
$0 MRX
MRX
0%
$0 HCAC
HCAC
0%
$0 
CGTX Cognition Therapeutics Inc.
-7.02%
-$20,257.7 
NAK Northern Dynasty Minerals Ltd.
-5.87%
-$0.06 
HSAI Hesai Group American Depositary Share
-4.42%
-$677.38 
MOB Mobilicom Ltd.
-3.58%
-$3,389.4 
VLO Valero Energy Corporation
-3.57%
-$174,380.51 
TOI The Oncology Institute Inc.
-2.84%
-$31,078.3 
PROF Profound Medical Corp.
-2.72%
-$37,506.42 
QNRX Quoin Pharmaceuticals Ltd. - American Depositary Receipt
-2.44%
-$21,498.7 
MPC Marathon Petroleum Corporation
-2.36%
-$25,945.46 
APYX Apyx Medical Corporation
-2.33%
-$1,814.94 
DRTS Alpha Tau Medical Ltd.
-2.1%
-$17,368.56 
POWL Powell Industries Inc.
-1.86%
-$3.16 
UNCY Unicycive Therapeutics Inc.
-1.76%
-$13,910 
TLSA Tiziana Life Sciences Ltd.
-1.43%
-$17,430 
AEXA American Exceptionalism Acquisition Corp. A
-1.11%
-$80.4 
AIRS AirSculpt Technologies Inc.
-1.06%
-$1,010.4 
CCXI ChemoCentryx Inc
-0.37%
-$1,543.48 
TRVI Trevi Therapeutics Inc.
-0.29%
-$0.04 
JBS JBS N.V.
-0.27%
-$23.59 
TVA Texas Ventures Acquisition Corp.
-0.14%
-$12.07 
RTAC Renatus Tactical Acquisition Corp.
-0.05%
-$9.06 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 355 | Longs Won 156/355 43% | Profit Factor 0.72 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $418,659.56 |
| Average Win $130,250.6 | Best Trade (Oct 14) $2.08M | Sharpe Ratio -30.83 |
| Average Loss -$142,002.46 | Worst Trade (Oct 14) -$4.81M | Z-Score -1.98 (98.37%) |
| Commissions $0 | Avg. Trade Length 5m 3w 1d | Expectancy -$21,707.54 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 287 | 259 | 230 | 201 | 172 | 144 | 115 | 86 | 57 | 29 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ADAG Adagene Inc. | 537,230 | $2.25M | $1.24M | - | -$1.01M | -44.76% | +0.873% |
| AEM Agnico Eagle Mines Limited | 165 | $27,812.4 | $30,500.25 | - | $2,687.85 | 9.66% | +4.429% |
| AEON Aeon Biopharma Inc. | 12.49M | $9.33M | $3.01M | - | -$6.32M | -67.72% | +5.374% |
| AEXA American Exceptionalism Acquisition Corp. A | 670 | $7,631.31 | $7,155.6 | - | -$475.71 | -6.23% | -1.111% |
| AIRS AirSculpt Technologies Inc. | 67,360 | $303,118.33 | $94,640.8 | - | -$208,477.53 | -68.78% | -1.056% |
| APYX Apyx Medical Corporation | 30,249 | $135,818 | $75,924.99 | - | -$59,893.01 | -44.1% | -2.335% |
| ARMP Armata Pharmaceuticals Inc. | 203,891 | $1.64M | $618,809.18 | - | -$1.02M | -62.21% | +9.173% |
| AZTR Azitra Inc. | 11.29M | $2.24M | $813,037.36 | - | -$1.42M | -63.64% | 0.0 |
| BKD Brookdale Senior Living Inc. | 4,571 | $73,547 | $46,304.23 | - | -$27,242.77 | -37.04% | +0.198% |
| CALM Cal-Maine Foods Inc. | 2,581 | $204,286.14 | $165,080.76 | - | -$39,205.38 | -19.19% | +1.219% |
| CAPR Capricor Therapeutics Inc. | 1 | $30.4 | $7.09 | - | -$23.31 | -76.68% | +7.663% |
| CCXI ChemoCentryx Inc | 38,587 | $673,343 | $416,353.73 | - | -$256,989.27 | -38.17% | -0.369% |
| CGTX Cognition Therapeutics Inc. | 371,701 | $501,796.35 | $268,442.46 | - | -$233,353.89 | -46.5% | -7.017% |
| CIB Bancolombia S.A. | 443 | $35,187 | $43,575.69 | - | $8,388.69 | 23.84% | +1.491% |
| COLO Global X MSCI Colombia ETF | 507 | $21,117 | $25,078.75 | - | $3,961.75 | 18.76% | +0.355% |
| COUR Coursera Inc. | 224,171 | $1.35M | $1.15M | - | -$203,302.73 | -15.01% | +6.095% |
| CRESY Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria - American Depositary Receipt | 80,186 | $898,885 | $907,304.59 | - | $8,419.59 | 0.94% | +1.389% |
| CRIS Curis Inc. | 500.05 | $5,500.55 | $300.03 | - | -$5,200.52 | -94.55% | +0.033% |
| DC Dakota Gold Corp | 581 | $2,934.05 | $3,111.25 | - | $177.2 | 6.04% | +2.195% |
| DRTS Alpha Tau Medical Ltd. | 61,200 | $769,896 | $808,831.44 | - | $38,935.44 | 5.06% | -2.102% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Matthew Okkerse?
The largest contributions to the portfolio's profits come from the following stocks: Northern Dynasty Minerals Ltd - $1.4M, Adecoagro S.A - $1.26M, Lincoln Educational Services Corporation - $1.24M, Okyo Pharma Ltd - $978,712.42, and Lineage Cell Therapeutics Inc - $943,760.82. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Femasys Inc - $2.41M, Myomo Inc - $661,943.65, Traws Pharma Inc - $331,949.53, Inmune Bio Inc - $219,985.77, and TScan Therapeutics Inc - $183,172.9. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Matthew Okkerse's portfolio generate?
The portfolio generates substantial dividend income, with a total of $341,458.82 earned over time. The largest contributors to dividend income include Vale S.A - $43,161.01, The St. Joe Company - $29,571.2, Valero Energy Corporation - $23,890.82, JBS N.V - $21,308, and PBF Energy Inc - $19,576.99. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Matthew Okkerse's monthly returns?
Matthew Okkerse's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Matthew Okkerse's strategy be considered aggressive or moderate?
Matthew Okkerse's strategy appears moderately aggressive. The portfolio shows a clear focus on growth, with noticeable volatility and risk exposure, although not to an extreme level. This type of strategy may appeal to users seeking higher returns while accepting meaningful fluctuations along the way.
Should beginners follow Matthew Okkerse's strategy?
Matthew Okkerse's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
2026 © Marketlog. All Rights Reserved.
